Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has been able to complete the manufacturing of its clinical-grade supply of AP-188 or DMT at Canadian manufacturer Dalton Pharma Services.
Moreau now feels the Company has produced a sufficient supply to complete its planned Phase 1 and Phase 2 clinical trials. Moreau also said the company has appointed Dr. Anthony Rudd and Dr. Robert Simister as medical consultants to the Company’s DMT stroke clinical research program.